Safety of Sotrovimab use in children with COVID-19: an Italian experience

J Chemother. 2023 Aug 21:1-4. doi: 10.1080/1120009X.2023.2250138. Online ahead of print.ABSTRACTSotrovimab is a monoclonal antibody approved in adult and adolescents at high risk for COVID-19. Thirty-three children evaluated in five Italian paediatric centres received Sotrovimab infusion and were retrospectively enrolled from December 2021 to April 2022. In more than half of cases (19/33, 57.6%) Sotrovimab was prescribed off-label. Overall, the infusion was well tolerated with no significative differences in those receiving an off-label prescription. All children had a complete recovery. Data on the safety of Sotrovimab should be investigated in a larger paediatric cohort, considering the continuous selection of new SARS CoV-2 variants which may be more or less susceptible to the effects of the Sotrovimab.PMID:37605372 | DOI:10.1080/1120009X.2023.2250138
Source: Journal of Chemotherapy - Category: Cancer & Oncology Authors: Source Type: research